PR
For a better future SCM Lifescience will do its best
Genexine and SCM Life Science Corporation Coimune, a U.S. corporation, approved by the U.S. FDA for a phase 2b clinical trial vaccine for metastatic renal carcinoma dendritic cells.
News
2022-01-28

CoImune, Inc., a U.S. joint venture between Genexine Co., Ltd. (CEO Sung Young-chul) and SCM Life Science Co., Ltd. (CEO Lee Byung-gun, SCM Life Science), has been approved by the FDA for phase 2b clinical trials of metastatic kidney cell carcinoma, a dendritic cell therapy. It's been about a year since Coimune was established. 

 

According to the approved plan, Coimune will recruit 90 subjects and conduct clinical trials by selecting five excellent clinical institutions, including MD Anderson Hospital, Mayo Clinic, Mass General Hospital, Fox Chase Cancer Hospital, and Emory University Hospital in the U.S. The first patient administration of a new drug is expected to be in the second quarter at the earliest.

 

Through this clinical trial, we will be able to confirm the clinical effectiveness of 'CMN-001' and we will do our best to achieve innovative results in the treatment field of kidney cancer patients, said Charles Nicolette, CEO of Coimune.

 

Meanwhile, SCM Life Science has recently submitted a securities report for listing on the KOSDAQ and is pushing for an IPO. The scheduled listing period is in late next month, and the organizer of the listing is Korea Investment & Securities.

 

 

 

 

LIST